IRADIMED CORPORATION to Hold 2017 Third Quarter Financial Results Conference Call on October 30th
October 16 2017 - 9:00AM
IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company
will release its 2017 third quarter financial results before the
market opens on Monday, October 30th.
IRADIMED management will host a conference call the same day
beginning at 11:00 a.m. Eastern Time to discuss those results and
to answer questions.
Individuals interested in listening to the conference call may
do so by dialing 1-844-413-1781 for domestic callers, or
1-716-247-5767 for international callers, and entering reservation
code 1131798.
The conference call will also be available real-time via the
Internet at http://www.iradimed.com/en-us/investors/events/. A
recording of the call will be available on the Company’s website
for 90 days following completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of
innovative MRI compatible medical devices. We are the only known
provider of non-magnetic intravenous (IV) infusion pump systems
that are specifically designed to be safe for use during magnetic
resonance imaging (MRI) procedures. We were the first to develop an
infusion delivery system that largely eliminates many of the
dangers and problems present during MRI procedures. Standard
infusion pumps contain magnetic and electronic components which can
create radio frequency (RF) interference and are dangerous to
operate in the presence of the powerful magnet that drives an MRI
system. Our patented MRidium® MRI compatible IV infusion pump
system has been designed with a non-magnetic ultrasonic motor,
uniquely-designed non-ferrous parts and other special features in
order to safely and predictably deliver anesthesia and other IV
fluids during various MRI procedures. Our pump solution provides a
seamless approach that enables accurate, safe and dependable fluid
delivery before, during and after an MRI scan, which is important
to critically-ill patients who cannot be removed from their vital
medications, and children and infants who must generally be sedated
in order to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system
has been designed with non-magnetic components and other special
features in order to safely and accurately monitor a patient’s
vital signs during various MRI procedures. The IRADIMED 3880
system operates dependably in magnetic fields up to 30,000 gauss,
which means it can operate virtually anywhere in the MRI scanner
room, including in very close proximity to the MRI scanner bore.
The IRADIMED 3880 has a compact, lightweight design allowing
it to travel with the patient from their critical care unit, to the
MRI and back, resulting in increased patient safety through
uninterrupted vital signs monitoring and decreasing the amount of
time critically ill patients are away from critical care units. The
features of the IRADIMED 3880 include: wireless ECG with
dynamic gradient filtering; wireless SpO2 using Masimo® algorithms;
non-magnetic respiratory CO2; non-invasive blood pressure; patient
temperature, and; optional advanced multi-gas anesthetic agent unit
featuring continuous Minimum Alveolar Concentration measurements.
The IRADIMED 3880 MRI compatible patient vital signs
monitoring system has an easy-to-use design and allows for the
effective communication of patient vital signs information to
clinicians. Our 3880 MRI compatible patient vital signs monitoring
system is currently available to international customers. Once we
receive FDA 510(k) clearance, the 3880 will be available to U.S.
customers. We currently anticipate commencing marketing the 3880 to
U.S. customers in the fourth quarter of 2017.
For more information please visit www.iradimed.com.
Media Contact:Chris ScottChief Financial OfficerIRADIMED
CORPORATION(407) 677-8022 InvestorRelations@iradimed.com
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jul 2023 to Jul 2024